Blackening of Sclera Due To Long Term Use of Minocycline

Tarig Mahmud Arian, Shahid Irfan, Asma Shaukat, Amna Shahid

Pak J Ophthalmol 2006, Vol. 22 No. 1

See end of article for authors affiliations

We report a case of blackening of sclera, skin, nails and oral cavity (mucosa, gums and teeth) in a patient who had used minocycline on a long term basis for acne rosacea. The patient showed remarkable improvement after the drug was stopped.

Correspondence to: Tariq Mahmud Arian Assistt Professor Department of Ophthalmology Quaid-I-Azam Medical Callege Bahawalpur

Received for publication September 2005

cnae rosacea is an inflammatory disorder predominantly affecting the central face. It is characterised by the presence of erythema, telengiectasia and superficial pustules! Men are more severely affected. Rosacea may also be complicated by various inflammatory disorders of the eye, including, keratitis, blepharitis, iritis, recurrent chalazion etc. These ocular problems are potentially sight threatening and warrant ophthalmologic evaluation!. Minocycline hydrochloride is a semi synthetic tetracycline derivative used widely for the treatment of acnae rosacea2. Patients receiving minocycline may experience vestibular toxicity, manifested by dizziness, ataxia, nausea, vomiting, diplopia, blurring of vision. Symptoms usually disappear after 24-48 hours cessation of tetracycline. The frequency of this side effect is directly related to dose and is more frequent in women than men1-2.

CASE REPORT

A 32 year old man presented with blurring of vision, diplopia, vertigo and black pigmentation of sclera. On examination it was noted that patient had subcutaneous pigmentation of his forehead, cheek, gums, teeth, mucosa of oral cavity and toe nails (Fig. 1). On past medical history patient was found to be taking minocycline 100 mg twice daily for the last 5 years for the treatment of acnae rosacea. Blood complete examination revealed: Haemo-globin 11 g/dl, Total Leukocyte Count 17,000/mm³, (Neutrophils, 34%, Lymphocytes, 60%, Eosinophils, 6%); Platelets 80,000/mm³.

The patient was asked to stop minocycline. Blurring of vision, diplopia and vertigo showed remarkable improvement after one week of cessation of the drug. However, pigmentation of the soft tissues, including sclera started to resolve after 6 months. But the pigmentation of teeth stayed even after 2 years.

DISCUSSION

Tetracycline has been used widely in bone growth studies³. Tetracycline accumulates in bone by absorption into the bone crystal surface and eventual incorporation into the crystal lattice. Onycholysis and pigmentation of nails may develop with or without accompanying photosensitivity^{2,4}. Brown discolouration of teeth may also occur. The larger the dose of drug relative to body weight, the more intense the









Fig. 1: Pigmentation of sclera, forehead, check gums and toe nails.

discolouration of enamel. This discolouration is permanent. The deposition of tetracycline in teeth and bones probably is due to its chelating properties and the formation of tetracycline-calcium orthophosphate complex^{5,6,7,8}. Blurring of vision, dizziness and vertigo have been particularly noted with 200-400mg/day of minocycline. Sixty five to seventy percent of the patients will have these reactions⁴.

Long-term therapy with tetracycline may produce changes in peripheral blood. Leukocytosis, atypical lymphocytes, toxic granulations of granulocytes and thrombocytopaenic purpura have been observed⁴⁹.

Author's affiliation

Dr. Tariq Mahmud Arain Assistant Professor, Ophthalmology Quaid-I-Azam Medical College Bahawalpur

Dr. Rashid Qamar Senior Registrar Bahawal Victoria Hospital Bahawalpur

Dr. Asma Shaukat Associate Professor, Pathology Quaid-I-Azam Medical College Bahawalpur

Dr. Shahid Irfan Assistant Professor, Medicine Quaid-I-Azam Medical College Bahawalpur

Dr. Amna Shahid Department of Gynaecology and Obsterics Bahawal Victoria Hospital Bahawalpur

REFERENCES:

- Lawly TJ, Primary cutaneous disorders.In:Harrison's Principles of Internal medicine.ed Richard MS, 15th ed. Pub. Me Grow Hill. New York, 2003; 1220-47.
- Eisen D Hakim MD. Minocycline-induced pigmentation. Incidence, prevention and management. Drug Saf. 1998, 18: 431–40.
- Westbury LW, Najera A. Minocycline-induced intraoral pharmacogenic pigmentation. Case reports and review of the literature. Periodontol 1997; 68: 84-91.
- Henry F. Tetrayclines. In Basic and Clinical pharmacology. eds. Katzung BG. 8th edition. Publisher. Lange. Newyork. 2003; 975-8.
- Wilkinson GR. Pharmakokinetics. In: The pharmacological basis of therapeautics. ed. Gilman AG. 10th ed. Pub. Me Grow Hill. New York. 2001; 3-10.

- Chambers HF. Antimicrobial Agents. In: Dermatological Pharmakokinetics. ed. Wyatt EL Pub. Me Grow Hill. New York; 2000; 1245-8.
- Fanning WL, Gump DW, Sofferman RA. Side effects of minocycline: a double-blind study. Antimicrobs Agents chemother. 1977; 11: 712-7.
- 8. Knabe C, Driessens FC, Planell JA, et al. Evaluation ofcalcium
- phosphatebone cements using osteogenic cultures. J Biomed Mater Res. 2000; 52: 498-508.
- Odell EW, Hodgson RP, Haskell R. Oral Presentation of minocycline-induced black bone disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995; 79: 459-61.